Healthcare / BiotechnologyTaipei Exchange
$32.00
+0.25 (+0.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $108.0M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
14.7x
↓EV/EBITDA
11.6x
↓ROE
15.0%
↑Gross Margin
85.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+68.5%
FCF CAGR
-11.6%
FCF margin
21.7%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $309.1M · net income $139.2M · FCF $67.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $309.1M | $309.1M | $249.0M | $181.4M | $64.6M |
| Net Income | $139.2M | $139.2M | $102.1M | $72.4M | $7.4M |
| EBITDA | $169.0M | $169.0M | $135.1M | $99.8M | $16.6M |
| EPS | — | — | 1.60 | 1.14 | 0.11 |
| Gross Margin | 85.1% | 85.1% | 82.5% | 79.7% | 60.9% |
| Operating Margin | 49.3% | 49.3% | 48.0% | 44.5% | 8.5% |
| Net Margin | 45.0% | 45.0% | 41.0% | 39.9% | 11.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 12.07 | 12.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $67.0M | $67.0M | $128.7M | $108.0M | $97.0M |
| Returns | |||||
| ROE | 15.0% | 15.0% | 12.2% | 9.5% | 1.1% |
| Valuation | |||||
| P/E | 14.68 | 14.68 | 32.58 | 47.02 | 384.62 |
| EV/EBITDA | 11.64 | 11.64 | 23.54 | 32.86 | 160.87 |
| P/B | 2.20 | 2.20 | 3.99 | 4.47 | 4.03 |
| Growth & Yield | |||||
| Revenue Growth | 24.1% | 24.1% | 37.3% | 180.8% | — |
| EPS Growth | — | — | 40.5% | 902.9% | — |
| Dividend Yield | 2.4% | 2.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.2%
Start / end P/E
n/dx → n/dx
EPS bridge
1.60 → n/d
Residual
-37.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.